BD to Showcase Advanced Drug Delivery and Traceability Innovations at CPhI 2025

FRANKLIN LAKES, N.J., October 27, 2025 / Biotech Newswire / -- BD (Becton, Dickinson and Company), a leading medical technology company, will feature the next generation of drug delivery and traceability solutions at CPhI 2025 on October 28-30 in Frankfurt, Germany. The event is a premier global platform for pharmaceutical professionals, focusing on innovations in drug delivery and packaging systems.

BD will showcase several technologies that help pharmaceutical and biotechnology companies advance the delivery of complex therapies — from high-viscosity biologics and GLP-1s to connected traceability systems that transform fill-finish operations.

Enabling next-generation biologic delivery
At CPhl, BD will highlight innovations that address growing demand for devices capable of delivering higher-volume, higher-viscosity drugs and enabling patient self-administration outside of traditional care settings.

Visitors can explore live demonstrations of:
* BD Libertas™ Wearable Injector – A ready-to-use, single-use wearable injector designed for subcutaneous delivery of large-volume, high-viscosity biologics. The system enables patients to self-administer therapies safely and comfortably without device assembly, supporting the move toward home-based care.
* BD Neopak™ XtraFlow™ Glass Prefillable Syringe with BD SCF™ PremiumCoat® Plunger Stopper – Designed for subcutaneous delivery of high-viscosity biologics, this integrated system features a shorter 8mm needle and thinner wall technology for improved injection performance, paired with a plunger stopper engineered to reduce glide force and glide force variability.(1*)

Driving new standards in fill-finish traceability
For the first time at CPhI, BD will host the BD iDiFill™ RFID Integration Tour, offering attendees an exclusive live demonstration of unit-level RFID traceability across the fill-finish process.

The guided tour will connect multiple manufacturing partners — BD, Bausch + Ströbel, Körber, and Harro Höfliger and feature insights from ten23 health — to showcase how BD iDiFill™ Individual Prefillable Syringe Identification supports regulatory compliance, manufacturing excellence, and data integrity from filling to final assembly.

Attendees can reserve a spot for this guided experience and see how RFID-enabled prefillable syringes are shaping the future of pharmaceutical manufacturing. BD iDFill Tour RFID Integration Tour - CPHI 2025

Integrated services to accelerate combination product development
BD and ZebraSci™ will also present a comprehensive range of combination product development services that support customers from concept through launch.

A continued commitment to partnership and innovation
“At BD, our mission is to make advanced drug delivery both possible and practical — enabling patients to receive complex biologics safely and conveniently, whenever and wherever,” said Fernand Goldblat, VP/GM, BD Medical – Pharmaceutical Systems, PFS Platform. “Our participation at CPhI underscores BD’s long-term commitment to collaborating with pharmaceutical and biotechnology partners to develop the next-generation of combination products and manufacturing solutions.”

BD will also display a selection of its broader drug delivery portfolio, including:
* BD Effivax™ Glass Prefillable Syringe for vaccines
* BD Hylok™ Prefillable Syringe for acute drugs and hyaluronic acid
* BD Physioject™ Disposable Autoinjector and BD Vystra™ Disposable Pen, both used for biologics such as GLP-1 therapies

Visit BD at CPhI 2025
Attendees can visit BD at booth #8.0C60 to meet BD experts, participate in live product demonstrations, and explore how BD’s integrated portfolio is shaping the future of drug delivery and traceability.

For more information, visit [bd.com/CPhI2025] or follow BD on LinkedIn and X for event updates.

About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 77,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/ and Twitter @BDandCo.
 
1. BD SCF™ PremiumCoat® Plunger Stopper 1-3mL Customer quality specifications. Le Pont-de-Claix, France; Becton, Dickinson and Company; 2023.
* When compared to the BD SCF™ FluroTec® Plunger Stopper. Results are based on a sample of 100 pieces of BD Flurotec® and BD SCF™ PremiumCoat®. Variables compared were Mean (glide force reduction) and standard deviation (glide force variability).
BD Libertas™ Wearable Injector is a product in development; some statements are forwarding looking and are subject to a variety of risks and uncertainties.
BD iDiFill™ Individual Prefillable Syringe Identification is under development and is not a released product; statements contained herein are forward-looking and are subject to a variety of risks and uncertainties. Actual product may vary.
PremiumCoat is a registered trademark of AptarGroup, Inc.
FluroTec is a registered trademark of West Pharmaceutical Services, Inc.
 
Keywords: Marketing; Drug Delivery Systems; Syringes; Glass;  Injections; Technology; Hospitals; Self Administration; Wearable Electronic Devices; Radio Frequency Identification Device; Viscosity; Glucagon-Like Peptide 1; Equipment Design; Biological Products; BD; Becton, Dickinson and Company; CPhI 2025; Frankfurt, Germany; drug delivery; traceability solutions; pharmaceutical packaging; biotechnology; high-viscosity biologics; GLP-1 therapies; traceability systems; fill-finish operations; home-based care; BD Libertas™ Wearable Injector; subcutaneous delivery; large-volume drug delivery; single-use injector; BD Neopak™ XtraFlow™ Glass Prefillable Syringe; BD SCF™ PremiumCoat® Plunger Stopper; high-viscosity biologic delivery; fill-finish traceability; BD iDiFill™ RFID Integration Tour; RFID-enabled prefillable syringes; regulatory compliance; pharmaceutical manufacturing; BD Effivax™ Glass Prefillable Syringe; BD Hylok™ Prefillable Syringe; BD Physioject™ Disposable Autoinjector; BD Vystra™ Disposable Pen